Methylene Blue Improves Onabotulinum Toxin A Injection Technique
Methylene blue aids observation of the procedure and assessment of drug distribution.
Adding methylene blue to onabotulinum toxin A (BTX-A) solution for the treatment of overactive bladder (OAB) facilitates observation of the procedure and assessment of drug distribution, researchers reported online ahead of print in the Scandinavian Journal of Urology.
Michal Szczypior, MD, and colleagues at the Medical University of Gdansk in Poland tested this approach in 30 patients (24 women and 6 men) with OAB who qualified for BTX-A injections. Each patients received 100 IU of BTX-A dissolved in 9.5 mL of 0.9% sodium chloride solution, with 0.5 mL of methylene blue added. Over the course of 600 injections, the investigators reported that they were unable to observe the exact distribution of the solution in only 43 injections in 7 patients. They found no pharmacologic interactions between methylene blue and BTX-A.